{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:08:52Z","timestamp":1790716132763,"version":"4.1.0"},"publisher-location":"Berlin, Heidelberg","reference-count":47,"publisher":"Springer Berlin Heidelberg","isbn-type":[{"value":"9783642624353","type":"print"},{"value":"9783642555800","type":"electronic"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2003]]},"DOI":"10.1007\/978-3-642-55580-0_20","type":"book-chapter","created":{"date-parts":[[2012,12,20]],"date-time":"2012-12-20T20:29:14Z","timestamp":1356035354000},"page":"273-288","source":"Crossref","is-referenced-by-count":30,"title":["Evaluation of Vitamin D Analogs as Therapeutic Agents for Prostate Cancer"],"prefix":"10.1007","author":[{"given":"Tai C.","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael F.","family":"Holick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bal L.","family":"Lokeshwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry L.","family":"Burnstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary G.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"20_CR1","first-page":"3","volume-title":"American Cancer Society","author":"American Cancer Society, Inc., Cancer Facts & Figures 2002","year":"2002","unstructured":"American Cancer Society, Inc., Cancer Facts & Figures 2002 (2002) American Cancer Society, Atlanta, Georgia, pp 3\u201315"},{"key":"20_CR2","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1007\/s001980050058","volume":"8","author":"MJ Barger-Lux","year":"1998","unstructured":"Barger-Lux MJ, Heaney RP, Dowell S, Chen TC, Holick MF (1998) Vitamin D and its major metabolites: serum levels after graded oral dosing in healthy men. Osteoporosis Int 8:222\u2013230","journal-title":"Osteoporosis Int"},{"key":"20_CR3","first-page":"265","volume":"9","author":"A Barreto","year":"2000","unstructured":"Barreto A, Schwartz GG, Woodruff P, Cramer SD (2000) 25-Hydroxyvitamin D3, the prohormone of 1,25-dihydroxyvitamin D3, inhibits the proliferation of primary cultures of prostate epithelial cells. Cancer Epidemiol Biomark Prev 9:265\u2013270","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"20_CR4","first-page":"1027","volume-title":"Feldman D","author":"L Binderup","year":"1997","unstructured":"Binderup L, Binderup E, Gotfredsen WO (1997) Development of new vitamin D analogs. In: Feldman D, Glorieux FH, Pike JW (eds) Vitamin D. Academic Press, San Diego, pp 1027\u20131043"},{"key":"20_CR5","first-page":"607","volume-title":"Feldman D","author":"NA Breslau","year":"1997","unstructured":"Breslau NA, Zerwekh JE (1997) Pharmacology of vitamin D preparations. In: Feldman D, Glorieux FH, Pike JW (eds) Vitamin D. Academic Press, San Diego, pp 607\u2013618"},{"key":"20_CR6","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1007\/BF00298580","volume":"56","author":"PM Byne","year":"1995","unstructured":"Byne PM, Freaney R, McKenna MJ (1995) Vitamin D supplementation of the elderly: review of safety and effectiveness of various regimes. Calcif Tissue Int 56:518\u2013520","journal-title":"Calcif Tissue Int"},{"key":"20_CR7","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1093\/jnci\/89.3.182","volume":"89","author":"MJ Campbell","year":"1997","unstructured":"Campbell MJ, Koeffler HP (1997) Toward the intervention of cancer with vitamin D Compounds. J Natl Cancer Inst 89:182\u2013183","journal-title":"J Natl Cancer Inst"},{"key":"20_CR8","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1046\/j.1365-2133.2000.03593.x","volume":"143","author":"TC Chen","year":"2000","unstructured":"Chen TC, Holick MF (2000) Hexafluoro-1,25-dihydroxyvitamin D3 has markedly increased potency in inhibiting proliferation of cultured human keratinocytes compared with 1,25-dihydroxyvitamin D3. Br J Dermatol 143:72\u201378","journal-title":"Br J Dermatol"},{"issue":"5","key":"20_CR9","first-page":"S262","volume":"23","author":"TC Chen","year":"1998","unstructured":"Chen TC, Young MV, Whitlatch LW, Zhu XH, Kong XF, Schwartz GG, Lokeshwar BL, Holick MF (1998) Expression and regulation of 25-hydroxyvitamin D3\u20131-alpha-hydroxylase in cultured human prostatic cells. Bone 23 [Suppl 5]: S262","journal-title":"Bone"},{"key":"20_CR10","first-page":"901","volume":"6","author":"TC Chen","year":"2000a","unstructured":"Chen TC, Schwartz GG, Burnstein KL, Lokeshwar BL, Holick MF (2000a) The in vitro evaluation of 25-hydroxyvitamin D3 and 19-nor-1a,25-dihydroxyvitamin D2 for prostate cancer therapy. Clin Cancer Res 6:901\u2013908","journal-title":"Clin Cancer Res"},{"key":"20_CR11","first-page":"525","volume-title":"Proceedings of the Eleventh workshopon vitamin D","author":"TC Chen","year":"2000","unstructured":"Chen TC, Whitlatch LW, Young MV, Flanagan JN, Schwartz GG, Lokeshwar BL, Kong XF, Xue P, Holick MF (2000b) Enhancement of 25-hydroxyvitamin D-1-alpha-hydroxylase activity in prostate cells by gene transfection: a novel approach for the treatment of prostate cancer. Vitamin D Endocrine Systsem: Structural, Biological, Genetic and Clinical Aspects. In: Norman AW, Bouillon R, Thomasset M (eds) Proceedings of the Eleventh workshopon vitamin D, Nashville, TN, May 27-June 1, 2000. University of California, Riversidepp 525\u2013528"},{"key":"20_CR12","first-page":"144","volume":"144","author":"A Dusso","year":"1994","unstructured":"Dusso A, Brown A, Slatopolsky E (1994) Extrarenal production of calcitriol. Semin Nephrol14:144\u2013155","journal-title":"Semin Nephrol"},{"key":"20_CR13","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1210\/en.141.1.5","volume":"141","author":"D Feldman","year":"2000","unstructured":"Feldman D, Zhao XY, Krishnan AV (2000) Vitamin D and Prostate Cancer. Endocrinology 141:5\u20139","journal-title":"Endocrinology"},{"key":"20_CR14","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1016\/S0022-5347(01)63236-1","volume":"159","author":"C Gross","year":"1998","unstructured":"Gross C, Stamey T, Hancock S, Feldman D (1998) Treatment of early recurrent prostate cancer with 1,25-Dihydroxyvitamin D3 (calcitriol). J Urol 159:2035\u20132040","journal-title":"J Urol"},{"key":"20_CR15","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.1002\/1097-0142(19921215)70:12<2861::AID-CNCR2820701224>3.0.CO;2-G","volume":"70","author":"CL Hanchette","year":"1992","unstructured":"Hanchette CL, Schwartz GG (1992) Geographic patterns of prostate cancer mortality: evidence for a protective effect of ultraviolet radiation. Cancer 70:2861\u20132869","journal-title":"Cancer"},{"key":"20_CR16","doi-asserted-by":"publisher","first-page":"803","DOI":"10.2174\/1381612003400371","volume":"6","author":"CM Hansen","year":"2000","unstructured":"Hansen CM, Hamberg KJ, Binderup E, Binderup L (2000) Seocalcitol (EB 1089): a vitamin Danalogue of anti-cancer potential, background, design, synthesis, pre-clinical and clinical evaluation. Curr Pharm Des 6:803\u2013828","journal-title":"Curr Pharm Des"},{"key":"20_CR17","first-page":"2852","volume":"61","author":"JY Hsu","year":"2001","unstructured":"Hsu JY, Feldman D, McNeal JE, Peehl DM (2001) Reduced 1a-hydroxylase activity in human prostate cancer cells correlates with decreased susceptibility to 25-hydroxyvitamin D3-inducedgrowth inhibition. Cancer Res 61:2852\u20132856","journal-title":"Cancer Res"},{"key":"20_CR18","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1172\/JCI108459","volume":"58","author":"MR Hughes","year":"1976","unstructured":"Hughes MR, Baylink DJ, Jones OG, Haussler M (1976) Radioligand receptor assay for 25-hydroxyvitamin D2\/D3 and 1 alpha, 25-dihydroxyvitamin D2\/D3. J Clin Invest 58:61\u201370","journal-title":"J Clin Invest"},{"key":"20_CR19","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/0003-9861(89)90562-6","volume":"268","author":"M Inaba","year":"1989","unstructured":"Inaba M, Okuno S, Nishizawa Y, Inoue A, Nishiawa Y, Morii H, DeLuca HF (1989) DNA binding property of vitamin D3 receptors associated with 26,26,26,27,27,27-hexafluoro-1,25-dihydroxyvitamin D3. Arch Biochem Biophys 268:35\u201339","journal-title":"Arch Biochem Biophys"},{"key":"20_CR20","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/pros.2990090306","volume":"9","author":"JT Isaacs","year":"1986","unstructured":"Isaacs JT, Isaacs WB, Feitz WF, Scheres J (1986) Establishment and characterization of seven Dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers. Prostate 9:261\u2013281","journal-title":"Prostate"},{"issue":"[Suppl2]","key":"20_CR21","doi-asserted-by":"publisher","first-page":"S48","DOI":"10.1053\/ajkd.1998.v32.pm9808143","volume":"32","author":"F Llach","year":"1998","unstructured":"Llach F, Keshav G, Goldblat MV, Lindberg JS, Sadler R, Delmex J, Arruda J, Lau A, Slatolpolsky E (1998) Suppression of parathyroid hormone secretion in hemodialysis patients by a novel vitamin D analogue:19-nor-1,25-Dihydroxyvitamin D2. Am J Kideny Dis 32 [Suppl2]: S48\u2013S54","journal-title":"Am J Kideny Dis"},{"key":"20_CR22","first-page":"241","volume":"8","author":"BL Lokeshwar","year":"1999","unstructured":"Lokeshwar BL, Schwartz GG, Selzer MG, Burnstein KL, Zhuang S-H, Block NL, Binderup L (1999) Inhibition of prostate cancer metastasis in vivo: a comparison of 1,25-dihydroxyvitamin D (calcitriol) and EB 1089. Cancer Epidemiol Biomark Prev 8:241\u2013248","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"20_CR23","first-page":"109","volume-title":"Vitamin D: molecular biology, physiology, and clinical applications. Humana Press","author":"PN MacDonald","year":"1999","unstructured":"MacDonald PN (1999) Molecular BIOLOGY OF THE VITAMIN D receptor. In: Holick MF (ed) Vitamin D: molecular biology, physiology, and clinical applications. Humana Press, Totowa, New Jersey, pp 109\u2013128"},{"key":"20_CR24","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1681\/ASN.V981427","volume":"9","author":"KJ Martin","year":"1998","unstructured":"Martin KJ, Gonzalez EA, Gellens M, Hamm LL, Abboud H, Lindberg J (1998) 19-nor-1,25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol 9:1427\u20131432","journal-title":"J Am Soc Nephrol"},{"key":"20_CR25","first-page":"515","volume":"52","author":"GJ Miller","year":"1992","unstructured":"Miller GJ, Stapleton GE, Ferrara JA, Lucia MS, Pfister S, Hedlund TE, Upadhya P (1992) The human prostatic carcinoma cell line LNCaP expresses biologically active, specific receptors for 1a,25-dihydroxyvitamin D3. Cancer Res 52:515\u2013520","journal-title":"Cancer Res"},{"key":"20_CR26","first-page":"695","volume":"5","author":"KA Moffatt","year":"1999","unstructured":"Moffatt KA, Johannes WU, Miller GJ (1999) 1a,25-Dihydroxyvitamin D3 and platinum drugs act synergistically to inhibit the growth of prostate cancer cell lines. Clin Cancer Res 5:695\u2013703","journal-title":"Clin Cancer Res"},{"key":"20_CR27","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/0169-6009(92)90823-V","volume":"16","author":"K Nakatsuka","year":"1992","unstructured":"Nakatsuka K, Imanishi Y, Morishima Y, Sekiya K, Sasao K, Miki T, Nishizawa Y, Katsumata T, Nagata A, Murakawa S, Morii H (1992) Biological potency of a fluorinated vitamin D analogue in hypoparathyroidism. Bone Miner 16:73\u201381","journal-title":"Bone Miner"},{"key":"20_CR28","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1021\/bi00605a021","volume":"17","author":"JL Napoli","year":"1978","unstructured":"Napoli JL, Fivizzani MA, Schnoes HK, DeLuca HF (1978) 1-a-hydroxy-25-fluorovitamin D3. V. A potent analogue of 1a,25-dihydroxyvitamin D3. Biochemistry 17:2387\u20132392","journal-title":"Biochemistry"},{"key":"20_CR29","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1097\/00001813-199110000-00007","volume":"2","author":"T Oikawa","year":"1991","unstructured":"Oikawa T, Yoshida Y, Shimamura M, Ashino-Fuse H, Iwaguchi T, Tominaga T (1991) Antitumor effect of 22-oxa-1a,25-dihydroxyvitamin D3: a potent angiogenesis inhibitor on ratmammary tumors induced by 7,12-dimethylbenz[a]anthracene. Anticancer Drugs 2:475\u2013480","journal-title":"Anticancer Drugs"},{"key":"20_CR30","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1146\/annurev.nutr.22.120501.150216","volume":"22","author":"JL Omdahl","year":"2002","unstructured":"Omdahl JL, Morris HA, May BK (2002) Hydroxylase enzymes of the vitamin D pathway: expression, function, and regulation. Annu Rev Nutr 22:139\u2013166","journal-title":"Annu Rev Nutr"},{"key":"20_CR31","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/1078-1439(95)00061-5","volume":"1","author":"JL Osborn","year":"1995","unstructured":"Osborn JL, Schwartz GG, Bahnson R, Smith DC, Trump DL (1995) Phase II trial of oral 1,25-Dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancer. Urol Oncol 1:195\u2013198","journal-title":"Urol Oncol"},{"key":"20_CR32","first-page":"805","volume":"54","author":"DM Peehl","year":"1994","unstructured":"Peehl DM, Skowronski RJ, Leung GK, Wong ST, Stamey TA, Feldman D (1994) Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. Cancer Res 54:805\u2013810","journal-title":"Cancer Res"},{"key":"20_CR33","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1021\/bi00001a045","volume":"34","author":"H Sasaki","year":"1995","unstructured":"Sasaki H, Harada H, Handa Y, Morino H, Suzawa M, Shimpo E, Katsumata T, Masuhiro Y, Matsuda K, Ebihara K (1995) Transcriptional activity of a fluorinated vitamin D analog on VDR-RXR-mediated gene expression. Biochemistry 34:370\u2013377","journal-title":"Biochemistry"},{"key":"20_CR34","first-page":"727","volume":"6","author":"GG Schwartz","year":"1997","unstructured":"Schwartz GG, Wang MH, Zhang M, Singh RJ, Siegal GP (1997) 1a,25-Dihydroxyvitamin D (calcitriol) inhibits the invasiveness of human prostate cancer cells. Cancer Epidemiol Biomark Prev 6:727\u2013732","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"20_CR35","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1159\/000110937","volume":"11","author":"GG Schwartz","year":"1992","unstructured":"Schwartz GG (1992) Multiple sclerosis and prostate cancer: what do their similar geographies suggest? Neuroepidemiology 11:244\u2013254","journal-title":"Neuroepidemiology"},{"key":"20_CR36","first-page":"1307","volume":"10","author":"GG Schwartz","year":"1990","unstructured":"Schwartz GG, Hulka BS (1990) Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). Anticancer Res 10:1307\u20131311","journal-title":"Anticancer Res"},{"key":"20_CR37","first-page":"1077","volume":"14","author":"GG Schwartz","year":"1994","unstructured":"Schwartz GG, Oeler TA, Uskokovic MR, Bahnson RR (1994) Human prostate cancer cell lines: inhibition of proliferation by vitamin D analogs. Anticancer Res 14:1077\u20131081","journal-title":"Anticancer Res"},{"key":"20_CR38","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/S0090-4295(99)80221-0","volume":"46","author":"GG Schwartz","year":"1995","unstructured":"Schwartz GG, Hill CC, Oele TA, Becich MJ, Bahnson RR (1995) 1,25-Dihydroxy-16-ene-23-yne-vitamin D3 and prostate cancer cell proliferation in vivo. Urology 46:365\u2013369","journal-title":"Urology"},{"key":"20_CR39","first-page":"727","volume":"6","author":"GG Schwartz","year":"1997","unstructured":"Schwartz GG, Wang M-H, Zhang M, Singh, RJ, Siegal GP (1997) 1a,25-Dihydroxyvitamin D (calcitriol) inhibits the invasiveness of human prostate cancer cells. Cancer Epidemiol Biomark Prev 6:727\u2013732","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"20_CR40","first-page":"391","volume":"7","author":"GG Schwartz","year":"1998","unstructured":"Schwartz GG, Whitlatch LW, Chen TC, Lokeshwar BL, Holick MF (1998) Human prostate cells synthesize 1,25-dihydroxyvitamin D3 from 25-hydroxy vitamin D3. Cancer Epidemiol Biomark Prev 7:391\u2013395","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"20_CR41","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1210\/en.132.5.1952","volume":"132","author":"RJ Skowronski","year":"1993","unstructured":"Skowronski RJ, Peehl DM, Feldman D (1993) Vitamin D and prostate cancer: 1,25-dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinology 132:1952\u20131960","journal-title":"Endocrinology"},{"key":"20_CR42","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1210\/en.136.1.20","volume":"136","author":"RJ Skowronski","year":"1995","unstructured":"Skowronski RJ, Peehl DM, Feldman D (1995) Actions of vitamin D3 analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3. Endocrinology 136:20\u201326","journal-title":"Endocrinology"},{"key":"20_CR43","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/0003-9861(84)90161-9","volume":"229","author":"Y Tanaka","year":"1984","unstructured":"Tanaka Y, DeLuca HF, Kobayashi Y, Ikekawa N (1984) 26,26,26,27,27,27-hexafluoro-1,25-dihydroxyvitamin D3: a high potent, long-lasting analog of 1,25-dihydroxyvitamin D3. Arch Biochem Biophys 229: 348\u2013354","journal-title":"Arch Biochem Biophys"},{"key":"20_CR44","doi-asserted-by":"publisher","first-page":"3467","DOI":"10.1210\/jc.86.8.3467","volume":"86","author":"ME Taplin","year":"2001","unstructured":"Taplin ME, Ho SM (2001) The endocrinology of prostate cancer. J Clin Endocrinol Metab 86:3467\u20133477","journal-title":"J Clin Endocrinol Metab"},{"key":"20_CR45","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/S0960-0760(02)00053-5","volume":"81","author":"LW Whitlatch","year":"2002","unstructured":"Whitlatch LW, Young MV, Schwartz GG, Flanagan JN, Burnstein KL, Lokeshwar BL, Rich ES, Holick MF, Chen TC (2002) 25-Hydroxyvitamin D-1a-hydroxylase activity is diminished in human prostate cancer cells and is enhanced by gene transfer. J Steroid Biochem Mol Biol 81:135\u2013140","journal-title":"Steroid Biochem Mol Biol"},{"key":"20_CR46","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1210\/en.139.3.1197","volume":"139","author":"S-H Zhuang","year":"1998","unstructured":"Zhuang S-H, Burnstein KL (1998) Antiproliferative effect of 1a,25-dihydroxyvitamin D3 in human prostate cancer cell line LplayNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation. Endocrinology 139:1197\u20131207","journal-title":"Endocrinology"},{"key":"20_CR47","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S0303-7207(96)03974-3","volume":"126","author":"S-H Zhuang","year":"1997","unstructured":"Zhuang S-H, Schwartz GG, Cameron D, Burnstein KL (1997) Vitamin D receptor content and transcriptional activity do not fully predict antiproliferative effects of vitamin D in human prostate cancer cell lines. Mol Cell Endocrinol 126:83\u201390","journal-title":"Mol Cell Endocrinol"}],"container-title":["Recent Results in Cancer Research","Vitamin D Analogs in Cancer Prevention and Therapy"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-642-55580-0_20.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T02:56:19Z","timestamp":1643943379000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-3-642-55580-0_20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003]]},"ISBN":["9783642624353","9783642555800"],"references-count":47,"URL":"https:\/\/doi.org\/10.1007\/978-3-642-55580-0_20","relation":{},"ISSN":["0080-0015"],"issn-type":[{"value":"0080-0015","type":"print"}],"subject":[],"published":{"date-parts":[[2003]]}}}